IN2014DN07996A - - Google Patents

Info

Publication number
IN2014DN07996A
IN2014DN07996A IN7996DEN2014A IN2014DN07996A IN 2014DN07996 A IN2014DN07996 A IN 2014DN07996A IN 7996DEN2014 A IN7996DEN2014 A IN 7996DEN2014A IN 2014DN07996 A IN2014DN07996 A IN 2014DN07996A
Authority
IN
India
Prior art keywords
compound
formula
pharmaceutically acceptable
provides
acceptable salt
Prior art date
Application number
Other languages
English (en)
Inventor
Fucheng Qu
Nathan Bryan Mantlo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN07996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IN2014DN07996A publication Critical patent/IN2014DN07996A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN7996DEN2014 2012-05-10 2013-05-02 IN2014DN07996A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645101P 2012-05-10 2012-05-10
US201361769221P 2013-02-26 2013-02-26
PCT/US2013/039164 WO2013169546A1 (en) 2012-05-10 2013-05-02 Pyrazole compounds as sglt1 inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN07996A true IN2014DN07996A (fi) 2015-05-01

Family

ID=48428684

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7996DEN2014 IN2014DN07996A (fi) 2012-05-10 2013-05-02

Country Status (43)

Country Link
US (2) US8697849B2 (fi)
EP (1) EP2850084B1 (fi)
JP (1) JP6148725B2 (fi)
KR (1) KR101685779B1 (fi)
AP (1) AP3593A (fi)
AR (1) AR090806A1 (fi)
AU (1) AU2013259946B2 (fi)
BR (1) BR112014026198B1 (fi)
CA (1) CA2869323C (fi)
CL (1) CL2014002845A1 (fi)
CO (1) CO7141429A2 (fi)
CR (1) CR20140473A (fi)
CY (1) CY1117912T1 (fi)
DK (1) DK2850084T3 (fi)
DO (1) DOP2014000250A (fi)
EA (1) EA024207B1 (fi)
EC (1) ECSP14026088A (fi)
ES (1) ES2588835T3 (fi)
GT (1) GT201400242A (fi)
HK (1) HK1202542A1 (fi)
HR (1) HRP20160804T1 (fi)
HU (1) HUE030414T2 (fi)
IL (1) IL235427A (fi)
IN (1) IN2014DN07996A (fi)
JO (1) JO3136B1 (fi)
LT (1) LT2850084T (fi)
MA (1) MA37501B1 (fi)
ME (1) ME02405B (fi)
MX (1) MX357058B (fi)
MY (1) MY177326A (fi)
NZ (1) NZ700356A (fi)
PE (1) PE20142399A1 (fi)
PH (1) PH12014502492A1 (fi)
PL (1) PL2850084T3 (fi)
PT (1) PT2850084T (fi)
RS (1) RS55107B1 (fi)
SG (1) SG11201407345QA (fi)
SI (1) SI2850084T1 (fi)
TN (1) TN2014000410A1 (fi)
TW (1) TWI579295B (fi)
UA (1) UA113086C2 (fi)
WO (1) WO2013169546A1 (fi)
ZA (1) ZA201407531B (fi)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
AR097890A1 (es) 2013-10-17 2016-04-20 Lilly Co Eli Compuestos de urea
AR098134A1 (es) 2013-11-01 2016-05-04 Lilly Co Eli Compuestos de urea
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN110054657B (zh) 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法
WO2019194207A1 (ja) * 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
EP4026564A4 (en) * 2019-09-04 2023-03-15 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC PROCEDURE FOR DIABETES USING COMBINATION MEDICATION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100591585B1 (ko) 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
JP4141258B2 (ja) 2001-02-26 2008-08-27 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体及びその医薬用途
US7217697B2 (en) 2001-05-30 2007-05-15 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor
NZ538117A (en) * 2002-08-08 2007-01-26 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
NZ573687A (en) * 2006-05-19 2010-10-29 Taisho Pharmaceutical Co Ltd C-phenyl glycitol compound for the treatment of diabetes
RU2482122C2 (ru) 2007-12-27 2013-05-20 Киссеи Фармасьютикал Ко., Лтд. Моносебацинат производного пиразола
ES2397086T3 (es) 2009-02-23 2013-03-04 Taisho Pharmaceutical Co., Ltd. Compuestos de 4-isopropilfenil glucitol como inhibidores de SGLT1
WO2011039338A2 (en) 2009-10-02 2011-04-07 Sanofi-Aventis Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
US20140162967A1 (en) 2014-06-12
CL2014002845A1 (es) 2015-01-30
CY1117912T1 (el) 2017-05-17
PE20142399A1 (es) 2015-01-22
BR112014026198A2 (pt) 2017-06-27
HRP20160804T1 (hr) 2016-08-12
CO7141429A2 (es) 2014-12-12
TN2014000410A1 (en) 2015-12-21
US20130303471A1 (en) 2013-11-14
MX357058B (es) 2018-06-25
WO2013169546A1 (en) 2013-11-14
EA201491852A1 (ru) 2015-02-27
AP2014008044A0 (en) 2014-11-30
EA024207B1 (ru) 2016-08-31
PH12014502492B1 (en) 2015-01-12
HUE030414T2 (en) 2017-05-29
EP2850084A1 (en) 2015-03-25
NZ700356A (en) 2016-06-24
CN104284894B (zh) 2016-02-17
AU2013259946B2 (en) 2015-09-10
JP2015516419A (ja) 2015-06-11
CR20140473A (es) 2014-11-21
SG11201407345QA (en) 2014-12-30
ECSP14026088A (es) 2015-09-30
TW201406773A (zh) 2014-02-16
ME02405B (me) 2016-09-20
AP3593A (en) 2016-02-15
DOP2014000250A (es) 2014-11-30
ES2588835T3 (es) 2016-11-07
MA37501B1 (fr) 2016-11-30
PL2850084T3 (pl) 2017-05-31
JP6148725B2 (ja) 2017-06-14
PT2850084T (pt) 2016-08-02
EP2850084B1 (en) 2016-06-15
CN104284894A (zh) 2015-01-14
LT2850084T (lt) 2016-09-12
US8697849B2 (en) 2014-04-15
BR112014026198B1 (pt) 2021-02-02
IL235427A (en) 2016-06-30
AR090806A1 (es) 2014-12-10
AU2013259946A1 (en) 2014-10-16
CA2869323C (en) 2016-03-29
KR20150001798A (ko) 2015-01-06
SI2850084T1 (sl) 2016-07-29
US9296775B2 (en) 2016-03-29
GT201400242A (es) 2015-08-27
MY177326A (en) 2020-09-11
RS55107B1 (sr) 2016-12-30
JO3136B1 (ar) 2017-09-20
MX2014013615A (es) 2015-02-12
KR101685779B1 (ko) 2016-12-12
UA113086C2 (xx) 2016-12-12
CA2869323A1 (en) 2013-11-14
MA37501A1 (fr) 2016-03-31
HK1202542A1 (zh) 2015-10-02
TWI579295B (zh) 2017-04-21
ZA201407531B (en) 2016-05-25
DK2850084T3 (en) 2016-09-12
PH12014502492A1 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
IN2015DN00598A (fi)
MX2015002040A (es) Baricitinib deuterado.
MX342879B (es) Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
IN2014DN07996A (fi)
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MX2015012629A (es) Compuestos de imidazo piridina.
RS54730B1 (sr) Inhibitori beta sekretaze
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
JO3318B1 (ar) مثبطات bace
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
IN2014CN04449A (fi)
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
MX364207B (es) Inhibidores de agrecanasa.
MX366983B (es) Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen.
MY160902A (en) Process for the preparation of the L-arginine salt of perindopril
MX2015008829A (es) Momelotinib deuterado.
CR20140114A (es) Compuestos de benzotiazolona
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
GB201020397D0 (en) Compounds
EA201690593A1 (ru) Новые соединения мочевины
MX2015012610A (es) Pacritinib deuterizado.
EA201690908A1 (ru) Пиразолопиримидиновые соединения